Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Walgreens further cuts stake in drug distributor Cencora

Published 05/22/2024, 06:26 PM
Updated 05/22/2024, 06:40 PM
© Reuters. FILE PHOTO: People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo
WBA
-

(Reuters) - Walgreens Boots Alliance (NASDAQ:WBA) sold $400 million worth of shares in drug distributor Cencora back to the company, further lowering its stake to about 12% from about 13%, the companies said on Wednesday.

The proceeds will be used primarily for debt paydown and general corporate purposes, Walgreens said.

For the past year, the pharmacy chain has been gradually reducing its stake in the drug distributor.

In November, Walgreens sold about $674 million worth of shares in Cencora and, prior to that, in August, sold some shares for proceeds of about $1.85 billion.

Walgreens owned about 15% in Cencora as of November last year.

© Reuters. FILE PHOTO: People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo

The sale has no impact to the long-term partnership between the two companies, Walgreens said.

Separately, Cencora said it is now raising its fiscal 2024 profit forecast to $13.35 to $13.55 per share, up from the previous range of $13.30 to $13.50 per share.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.